Perspective shares Phase 1/2a data: 33% and 50% response rates in two dose cohorts
Perspective Therapeutics reported updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in advanced SSTR2-expressing neuroendocrine tumors, presented at the ESMO Congress 2026 on October 23, 2026. The company reported objective response rates of 33% in Cohort 2 and 50% in Cohort 3, with no dose-limiting toxicities and no discontinuations due to adverse events, and it aims to complete Phase 3 site start-up preparations around year-end 2026. The data are early and based on small cohorts, so the results may not hold as the trial continues.
Key points
- Objective response rate was 33% (15 of 46) in Cohort 2 at 5.0 mCi and 50% (10 of 20) in Cohort 3 at 6.0 mCi, including unconfirmed responses
- Progression-free survival was 72% at 18 months across all patients who received at least one treatment
- 20 of 68 patients (29%) had high-grade treatment-emergent adverse events, all Grade 3; no dose-limiting toxicities were reported
- Phase 3 site start-up preparations targeted around year-end 2026, with Phase 3 initiation expected in 2027 following an End-of-Phase 2 meeting with the FDA
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.